Literature DB >> 11186135

Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank.

M B Fisher1, M Vandenbranden, K Findlay, B Burchell, K E Thummel, S D Hall, S A Wrighton.   

Abstract

The variability in a liver bank and tissue distribution of three probe UDP-glucuronosyltransferase (UGT) activities were determined as a means to predict interindividual differences in expression and the contribution of extrahepatic metabolism to presystemic and systemic clearance. Formation rates of acetaminophen-O-glucuronide (APAPG), morphine-3-glucuronide (M3G), and oestradiol-3-glucuronide (E3G) as probes for UGT1A6, 2B7, and 1A1, respectively, were determined in human kidney, liver, and lung microsomes, and in microsomes from intestinal mucosa corresponding to duodenum, jejunum and ileum. While formation of E3G and APAPG were detectable in human kidney microsomes, M3G formation rates from kidney microsomes approached the levels seen in liver, indicating significant expression of UGT2B7. Interestingly, rates of E3G formation in human intestine exceeded the hepatic rates by several fold, while APAPG and M3G formation rates were low. The intestinal apparent Km value for E3G formation was essentially identical to that seen in liver, consistent with intestinal UGT1A1 expression. No UGT activities were observed in lung. Variability in APAPG and M3G activity across a bank of 20 human livers was modest (< or = 7-fold), compared to E3G formation, which varied approximately 30-fold. The E3G formation rates were found to segregate by UGT1A1 promoter genotype, with wild-type (TA)6 rates significantly greater than homozygous mutant (TA)7 individuals. Kinetic analyses were performed to demonstrate that the promoter mutation altered apparent Vmax without significantly affecting apparent Km. These results suggest that glucuronidation, and specifically UGT1A1 activity, can profoundly contribute to intestinal first pass metabolism and interindividual variability due to the expression of common allelic variants.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11186135     DOI: 10.1097/00008571-200011000-00007

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  17 in total

Review 1.  Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.

Authors:  Timothy W Harper; Patrick J Brassil
Journal:  AAPS J       Date:  2008-04-05       Impact factor: 4.009

2.  A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.

Authors:  Sebastian Frechen; Lisa Junge; Teijo I Saari; Ahmed Abbas Suleiman; Dennis Rokitta; Pertti J Neuvonen; Klaus T Olkkola; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2013-09       Impact factor: 6.447

3.  Contributions of Hepatic and Intestinal Metabolism to the Disposition of Niclosamide, a Repurposed Drug with Poor Bioavailability.

Authors:  Xiaoyu Fan; Hongmin Li; Xinxin Ding; Qing-Yu Zhang
Journal:  Drug Metab Dispos       Date:  2019-04-30       Impact factor: 3.922

4.  Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception.

Authors:  Noam Zelcer; Koen van de Wetering; Michel Hillebrand; Elise Sarton; Annemieke Kuil; Peter R Wielinga; Thomas Tephly; Albert Dahan; Jos H Beijnen; Piet Borst
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-10       Impact factor: 11.205

5.  Comparing the metabolism of quercetin in rats, mice and gerbils.

Authors:  Shu-Lan Yeh; Yi-Chin Lin; Yi-Ling Lin; Chien-Chun Li; Cheng-Hung Chuang
Journal:  Eur J Nutr       Date:  2015-02-19       Impact factor: 5.614

6.  Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates.

Authors:  Jeroen W B Peters; Brian J Anderson; Sinno H P Simons; Donald R A Uges; Dick Tibboel
Journal:  Intensive Care Med       Date:  2005-01-28       Impact factor: 17.440

7.  Farnesol is glucuronidated in human liver, kidney and intestine in vitro, and is a novel substrate for UGT2B7 and UGT1A1.

Authors:  Adam G Staines; Pavel Sindelar; Michael W H Coughtrie; Brian Burchell
Journal:  Biochem J       Date:  2004-12-15       Impact factor: 3.857

8.  Mapping of a quantitative trait locus for morphine withdrawal severity.

Authors:  Benjamin Kest; Christina A Palmese; Aaron Juni; Elissa J Chesler; Jeffrey S Mogil
Journal:  Mamm Genome       Date:  2004-08       Impact factor: 2.957

9.  Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes.

Authors:  Vincent C Peterkin; Jonathan N Bauman; Theunis C Goosen; Lee Menning; Michael Z Man; Joseph D Paulauskis; J Andrew Williams; Scott P Myrand
Journal:  Br J Clin Pharmacol       Date:  2007-06-06       Impact factor: 4.335

Review 10.  Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).

Authors:  Kathleen M Knights; Andrew Rowland; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.